Molecular BIology of Cancer Topics
Some cancers are itrinsically resistant to chemotherapy: lung, colon, kidney, liver, pancreaas. These cancers are major causes of cancer deaths. Other cancers initially respond to chemotherapy, but become refractory/resistant, i.e. aquire drug resistance. Drug resistance is the primary cause of cancer chemotherapy failure.
Drug resistance is due to genetic changes in the tumor (gene amplification, point mutation ?), for example amplification of dihydrofolate reductase leads to resistance to methotrexate.
So drug resistance is mediated by transport proteins like P-glycoprotein, am ATP-dependent transmembrane pump found on the plasma membrane of cells that line tubules or ducts in the kidney, lung, liver and colon. P-glycoprotein may play a general role in excretion of substances from cells. Elevation of P-glycoprotein levels leads to resistance to many chemotherapeutic agents by decreasiong drug uptake and retention by the tumor cell. Competitive substrates for P-glycoprotein, e.g verapamil, modulate drug resistance.
The gene coding for P-glycoprotein is known as mdr1 (multidrug resistance). Drug-resistant human tumors have elecated mdr1. Transfection of mdr1 confers the drug-resistance phenotype.
p53 causes G1 growth arrest in most cells and apoptosis in some cells (thymocytes) in response to DNA damage. p53 positive tumor cells are more responsive to radiation or chemotherapeutic treatment. An it seems like the inhability of p53-negative cells to uncergo apoptosis confers them resistance to chemotherapy with many different drugs. Transfection of wild-type p53 into p53-negative cells restore their sensibility to chemotherapeutic drugs. Experimentally, apoptosis in response to some chemotherapeutic drugs occur only in the presence of wild-type p53. p53 induces apoptosis by actin as a transcription factor of the human Bax gene.
Antiangiogenic therapy of experimental cancers does not induce acquired drug resistance (Boeh et. al. 1997; Nature 390:27). Successive cycles of therapy using anti-tumor agents leads to acquired drug resistance as a result of selection of drug-resistant tumor cels. In contrast, repeated treatment with an angiogenesis inhibitor such as endostatin does not induce resistance in its target cells (endothelial vascular cells). By attacking the endothelial cells of the new blood vessels being formed to nourish the grwing tumor, angiogenesis inhibitors destroy the source of nutrients to the tumor, which regressess and may becoe dormant.
Several cancer types are progressed by sex hormones. 20% of prostate cancers are responsive to dihydrotestosterone. 40% of female cancers are responsive to estrogen or progesterone: breat, ovarian, endometrial.
Breast cancer is the leading cancer in U.S. women (1 in 8 women), second only to lung cancer in causing death. Patients with localized breast cancer usually suvive more than 5 years after treatment (96% survival). 78% of patients with regional disease (lymph nodes) and 21% with metastatic disease survive 5 years after treatment. The main risk factors for breast cancer are (1) having a first degree relative (mother, sister) with breast cancer, and (2) high total lifetime exposure to "unopposed" estrogen. Less than 10% of breast cancers are inherited, due to BECA1 or BRCA2 gene mutations.
The concept of unopposed estrogens refers to the blocking effect of progesterone on estrogen receptor production. This usually hapens naturally during pregnancy, when both estrogen and progesterone are present in high quantities. Events that would increase the lifetime exposure to unopposed estrogen are an early menarche, later age at first pregnancy and late menopause.
The estrogen receptor belongs to the family of nuclear steroid receptors. Activated ER forms homodimers that bind the Estrogen Response Element (ERE) in the promoter region of genes controlled by estrogen.
Estrogens have many effects in tissues. They stimulate growth in breast and endometrium, and increases bone density. In the cardiovascular system, it lowers serum cholesterol. At puberty, estrogen enhances growth of reproductive organs, genitalia and breasts. During pregnancy it increases proliferation of mammary gland tissue and ducts.
Breast cancer arrises from breast ductal epithelial cells. Mammary tumor growth is dependent on estrogen. Tumor growth is greately reduced by ovarectomy, and is restored by exogenous estrogen. Anti estrogens lilke tamoxifen have antitumor activity. Tamoxifen binds to the estyrogen receptor and have antiestrogenic effects in the breast, while having estrogenic effects in the endometrium (probably due to different transcriptional coactivators expressed in each tissue). Antiestrogens such as tamoxifen may be useful in the treatment and prevention of human breast cancer. Since ER+ and progesterone receptor positive (PR+) tumors are the most responsive to hormonal therapy, human breast cancers are tested for the presense of these receptors in order to determine if antiestrogen therapy is appropriate.
The End !!" or take a quiz: [Q1].
Need more practice? Answer the review questions below.
1- List 5 cancers
that are intrinsically resistant to chemotherapy.
lung
colon
kidney
liver
pancreas
2- What is the
primary cause of chemotherapy failure?
drug resistance
3- What is(are)
the cause(s) of drug resistance?
Genetic changes in a tumor that either amplify a protein that increases
drug resistance or makes it constitutively active, or makes a protein that
facilitates drug action non-fuctional.
4- Which mutation
makes cancer resistnt to methotrexate?
Amplification
of dihydrofolate reductase.
5- What is P-glycoprotein?
Transport
protein that mediates drug resistance, and ATP-dependent transmembrane pump
normally found in the plasma membrane of cells that line tubules and ducts
in the kidneys, lung, liver and colon. May play a general role in the excretion
of substances from cells.
6- What is the
outcome of P-glycoprotein amplification?
Elevation
of P-glycoprotein levels leads to resistance to many chemotherapeutic agents
by decreasing drug uptake and retention by tumor cells.
7- How can P-glycoprotein-mediated
drug resistance be modulated?
By using
competitive substrates like verapamil.
8- What is mdr1
and how it affects cancer cells?
Gene
coding for P-glycoprotein. Drug-resistant human tumors have elevated mdr1.
Transfection of mdr1 confers the drug resistance phenotype.
9- Explain how
mutations of p53 can confer drug resistance to a tumor.
p53 causes
G1 arrest in most cells and apoptosis in some cells in response to DNA damage.
p53-positive tumor cells are more responsive to radiation or chemotherapy
treatments. The inhability of p53-negative cells to undergo apoptosis confers
them resistance to chemotherapy with many different drugs. Transfection
of wild-type p53 into p53-negative cells restores their sensitivity to chemotherapy.
Experimentally, apoptosis in response to some drugs occur only in the prescence
of wild-type p53.
10- How does
p53 causes apoptosys?
By acting
as transcription factor of the human Bax gene which codes for a proapoptotic
protein.
11- What is
the mechanism of action of endostatin?
While
successive cycles of therapy with anti-tumor agents can lead to aquired
drug resistance, repeated treatments with the angiogenesis inhibitor endostatin
does not induce resistance. By attacking the endothelial cells of new blood
vessels, endostatin destrois the source of nutrients to the tumor, which
eventually regresses and may become dormant.
12- xxx.
xxx.
13- xxx.
xxx.
14- xxx.
xxx.
15- xxx.
xxx.
16- xxx.
xxx.
17- xxx.
xxx.
18- xxx.
xxx.
19- xxx.
xxx.
20- xxx.
xxx.
21- xxx.
xxx.
22- xxx.
xxx.
23- xxx.
xxx.
24- xxx.
xxx.
25- xxx.
xxx.
26- xxx.
xxx.
27- xxx.
xxx.
28- xxx.
xxx.
29- xxx.
xxx.
Continue scrolling to answers below.
Hey! DON'T PEEK!!! Finish the questions fist!
Answers under construction